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Objectives: To assess the problems faced by pregnant women with prosthetic cardiac valves in terms of maternal and 
neonatal outcomes.
Settings: Tertiary‑level teaching hospital.
Population: All pregnant women with prosthetic cardiac valves visiting the hospital in the period between January 2008 
and September 2012. 
Method: Retrospective observational case series study.
Results: Among the women presenting for antenatal visits to the hospital in the study period, eight were found to be have 
prosthetic cardiac valves. All cases had rheumatic origin of their cardiac lesion. Five cases had a mitral valve replacement. 
One had aortic and two had double‑valve replacement. All patients had mechanical valves and were on anticoagulant 
regimen. Among them, one patient developed valve thrombosis and another developed embolic transient ischemic attack 
while in labor. Two patients developed symptomatic arrhythmia requiring treatment, while one patient had pneumonia with 
parapneumonic effusion. Three cases had abortions, while the other five pregnancies delivered live babies. All deliveries 
took place by lower segment Caesarean section (LSCS) for indications other than the cardiac condition. One pregnancy 
was complicated by intrauterine growth restriction and oligohydramnios. No patient developed any complications during the 
LSCS. There were no cases of warfarin embryopathy observed.
Conclusion: Maternal complications tend to be higher in pregnant women with prosthetic cardiac valves requiring strict 
adherence to anticoagulant regimens and specialized treatment in tertiary care centers.
Key words: Anticoagulation; prosthetic cardiac valves; warfarin.
Introduction
Cardiovascular disorders affect approximately 0.3%–3.5% 
of all pregnancies.[1] The physiological changes in the 
cardiovascular system brought about by pregnancy tend 
to accentuate the condition causing further worsening 
and an increased propensity for cardiac failure particularly 
during the midtrimester, labor, and immediate postpartum 
period.[2] With the high prevalence of rheumatic heart disease 
in India,[3] the prevalence of prosthetic cardiac valves use is 
also in the same measure. Pregnancy in women with this 
condition presents with its unique set of problems as regards 
the maternal and fetal outcome due to the condition itself 
and the use of anticoagulants pertinent to it.
In women with prosthetic cardiac valves, on one hand while 
the functional class is improved with placement of the artificial 
valve remedying the cardiac lesion in question, a fresh set of 
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problems is created with regard to anticoagulation measures 
needed in case of metallic valves.[4] Pregnancy on account 
of its hypercoagulability renders the dose of anticoagulants 
being taken insufficient and inadequate while the choice of 
the drugs also becomes a dilemma considering the effect of 
the drugs on the fetus. While warfarin has been found to have 
good anticoagulation, it is fraught with risks of teratogenesis 
and maternal hemorrhage, while heparin, both unfractionated 
and low-molecular weight, having minimal fetal effects is 
often found not to cope up with the increased demands 
of pregnancy.[5] The fetal outcomes in these complicated 
pregnancies also tend to be below par with affected maternal 
cardiovascular system also compromising the uteroplacental 
circulation. There is also the risk of development of anomalies 
due to the use of warfarin which has lifelong consequences 
for the fetuses born alive.[6] All these problems make it 
mandatory for such pregnancies to be monitored and treated 
for complications in a tertiary healthcare setting which may 
improve if not totally abdicate the effects of the underlying 
condition on the maternal and fetal outcome.
India is a country with grave problems of poverty and 
illiteracy which adds onto these serious problems. Even 
after guidelines issued by the American Association of 
Cardiologists regarding the anticoagulation regimens to be 
followed in pregnancy,[4] their compliance and adherence 
becomes difficult both due to ignorance and financial reasons.
We undertake this study to assess the problems faced by 
pregnant women with prosthetic cardiac valves and the 
challenges faced while treating them.
Materials and Methods
It was a retrospective observational study conducted in the 
obstetrics and gynecology and cardiology departments of a 
tertiary care center. Being a retrospective study, no ethical 
clearance was required to be obtained for the same. The 
Hospital records for the period of January 2008-September 2012 
were studied, and all pregnant patients found to have prosthetic 
cardiac valves were included. The patient’s records were 
observed for the problems faced due to pregnancy, the cardiac 
condition, the anticoagulation regimens followed, and delivery. 
Patients were analyzed for New York Heart Association (NYHA) 
class at the time of conception, anticoagulation during 
pregnancy, ECHO findings at the time of presentation, outcome 
of pregnancy, and cardiac and obstetric complications.
Results
In the given study period, 144 patients were found to have 
cardiac disease complicating their pregnancies. Among them, 
eight patients were found to have prosthetic cardiac valves 
and hence were suitable for the study. None of the patients 
had bioprosthetic valves which are associated with fewer 
complications on account of no need for anticoagulation. All 
the patients had cardiac valve replacement due to a lesion 
of rheumatic origin which is more common in a country like 
India. Only one patient had an uncomplicated pregnancy 
while all the other patients had either maternal or fetal 
complications. Most complications were due to cardiac 
reasons than obstetric ones. The cases are summarized as 
follows:
Case I: Mrs. S, a 24-year-old primigravida at 7+ weeks, 
presented to the hospital with complaints of breathlessness 
on exertion. The patient had severe pulmonary arterial 
hypertension, moderate pulmonary regurgitation/
tricuspid regurgitation, and severe aortic root and 
subvalvular obstruction. The patient was in NYHA Class II 
in sinus rhythm and not in failure. She had undergone 
aortic valve replacement and transpulmonary patent 
ductus arteriosus closure 10 years back. She was on tablet 
warfarin and aspirin and had conceived on the same. 
Electrocardiogram done showed right bundle branch block 
and right ventricular hypertrophy. Ultrasound pelvis was 
suggestive of missed abortion.
After stopping warfarin and changing over to heparin for 
better coagulation control, suction evacuation of pregnancy 
was done. Warfarin was restarted following the procedure.
The patient improved symptomatically and was discharged. 
She was advised against future conception and levonorgestrel 
intrauterine system was recommended for the same.
Case II: Mrs. S, a 31-year-old G2MTP1, presented to the 
hospital at 24+ weeks for antenatal checkups. She had mitral 
regurgitation and aortic regurgitation and had undergone 
aortic and mitral valve replacement 3 years back. She was in 
NYHA Class I in sinus rhythm and not in failure at the time 
of presentation. She had conceived while on tablet aspirin, 
warfarin, and ramipril.
In view of its fetotoxic effects, ramipril was stopped 
immediately.[7] As the patient had presented in second 
trimester, warfarin and aspirin were continued. Anomaly 
scan done showed no evidence of anomalies in the fetus. 
She continued to have regular checkups in the hospital 
and her coagulation parameters were regularly monitored. 
Ultrasound later in pregnancy showed adequate interval 
growth of the fetus. At the onset of third trimester, warfarin 
was stopped and low-molecular-weight heparin (LMWH) 
was started.
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At the onset of labor, as epidural analgesia was provided, 
heparin was stopped. However, the patient complained of 
headache after sometime. She was diagnosed to have embolic 
transient ischemic attack and heparin was restarted. In view 
of nonprogress of labor, emergency lower segment Caesarean 
section (LSCS) was finally done and the patient delivered a 
healthy female baby with a weight of 3.1 kg. Post delivery, 
the patient was restarted on warfarin and discharged.
Case III: Mrs. S, a 34-year-old primigravida at 27+ weeks, 
referred to the hospital from a secondary care center in view 
of impaired glucose tolerance test. She had undergone mitral 
valve replacement 2 years back. She had history of embolic 
stroke 1 year back leading to hemiparesis with weakness 
persisting. She was on tablet warfarin and clopidogrel with 
penicillin prophylaxis at the time of conception. Warfarin 
had been changed to unfractionated heparin from 6 to 
14+ weeks. The patient was in NYHA Class I in sinus rhythm 
at the time of presentation.
The patient was put on diabetic diet in view of her blood sugar 
levels. She also received steroid prophylaxis at 28+ weeks.
Warfarin was changed over to heparin from 33+ weeks. She 
underwent elective LSCS at 36+ weeks in view of intrauterine 
growth restriction, oligoamnios, and gestational diabetes 
mellitus. She delivered a male baby weighing 2.28 kg. There 
were no complications postnatally.
Case IV: Mrs. J, a 28-year-old G3Ab2 at 6+ weeks, presented 
to the hospital with chest pain and palpitations. She had 
undergone mitral valve replacement 9 years back. The patient 
had stopped warfarin preconceptionally and had conceived 
on heparin. She was in NYHA Class IV in atrial fibrillation and 
failure at the time of presentation. She was started on beta 
blockers, diuretics, and digoxin. Ultrasound pelvis showed a 
live fetus of 6+ weeks. She was advised medical termination 
of pregnancy, but she refused.
The patient developed severe abdominal pain and 
breathlessness 2 days later. She was found to have bradycardia 
and hypotension. She was administered inotropes but had a 
cardiac arrest and could not be revived.
Case V: Mrs. M, a 28-year-old G3P2L1ID1 at 34+ weeks, 
referred from a secondary care center with polyhydramnios. 
The patient had undergone mitral valve replacement 4 years 
back. She had conceived on warfarin and metipril and was in 
NYHA Class I and sinus rhythm at the time of presentation.
Warfarin was changed over to Heparin and steroid prophylaxis 
was given. Growth scan showed adequate interval growth. The 
patient underwent elective LSCS with sterilization at term in view 
of cephalopelvic or fetopelvic disproportion (CPD). She delivered 
a female baby of 2.7 kg. She developed arrhythmia on the second 
postop day and was treated with diltiazem and adenosine. She 
was started back on warfarin at the time of discharge.
Case VI: Mrs. M, a 32-year-old primigravida, presented at 
5+ weeks for antenatal checkups. She had undergone mitral 
valve replacement 6 years back and had conceived while on 
warfarin, penicillin, and losartan. The patient was in NYHA 
Class I and sinus rhythm at the time of presentation.
In view of fetotoxicity, losartan was changed to torsemide 
and warfarin was switched over to heparin till 15+ weeks 
and then restarted back. The patient was monitored 
regularly with scans and blood coagulation parameters which 
remained within the normal range. She was found anemic 
at 21+ weeks which was resolved with double-dose iron. 
Steroid prophylaxis was given at 28+ weeks and growth scan 
was normal. Heparin was restarted again at 34+ weeks. The 
patient delivered a healthy male baby of 2.8 kg at term by 
elective LSCS done in view of floating head at term. There 
were no complications postnatally.
Case VII: Mrs. S, a 33-year-old primigravida, presented at 
32+ weeks with breathlessness. The patient had undergone 
mitral valve replacement 8 years ago. She had conceived 
on warfarin and aspirin and was in NYHA Class II and sinus 
rhythm at the time of presentation. She had regular checkups 
in a secondary care center previously.
She was diagnosed to have right-sided lobar pneumonia and 
parapneumonic effusion which was treated with antibiotics. 
Growth scan was normal. The patient was switched over to 
heparin at 35+ weeks and underwent elective LSCS at term 
in view of CPD. She delivered a healthy female baby of 3.2 kg. 
There were no complications postnatally.
Case VIII: Mrs. I, a 35-year-old G2MTP1 at 6+ weeks, 
presented for antenatal checkups. She underwent mitral valve 
replacement 2 years back and had conceived on warfarin. 
She was in NYHA Class I and sinus rhythm at the time of 
presentation. The patient was started on unfractionated 
heparin 5000 U sc bd. However at 10+ weeks, she took 
a lower dose of heparin than prescribed for 3 days and 
reported back with bleeding per vaginum. She was found 
to be with inevitable abortion. Suction evacuation was 
done and she was started on heparin eighth hourly. The 
patient developed chest pain and breathlessness the next 
day. ECHO was suggestive of valve thrombosis. She was 
started on streptokinase but the thrombus persisted. She 
had cardiac arrest the next day and was declared dead after 
failed cardiopulmonary resuscitation.
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The NYHA Class of most of these patients was either I 
or II at presentation. The only patient in Class IV died in 
the first trimester. But as she had stopped her warfarin 
preconceptionally on medical advice, it indicates she was 
in a better class at the time of her conception. This shows 
that the NYHA classification may not have much bearing 
on the ultimate prognosis of the patient though it may be 
used preconceptionally to decide whether a patient is fit for 
pregnancy or not.
As per the current guidelines proposed by the American 
College of Cardiologists and chest physicians,[4] it is 
recommended to stop warfarin in the first trimester, that 
is, from 6 to 12 weeks to prevent warfarin embryopathy 
and replace it with heparin, but most patients in the series 
continued warfarin well upto the third trimester. This was 
because these patients were getting their checkups done at 
secondary care centers where this protocol was not followed 
and presented late at the center of study. No cases of warfarin 
embryopathy were observed among the patients who 
delivered live babies. This is comparable to studies by Tounsi 
et al.[10] and Suri et al.[11] which found a very low incidence of 
anomalies in babies where patients continued taking warfarin 
in the first trimester. Most studies have found a higher risk 
of fetal loss in patients on warfarin throughout pregnancy; 
however, in our series, this has happened with only one 
patient. The two other patients who had fetal loss had been 
started on heparin. The fact that these two had maternal loss 
as well makes warfarin appear a much preferential treatment 
than heparin.
Most	of	these	patients	were	on	a	dose	of	warfarin	<5	mg/day	
which is associated with less incidence of embryopathy which 
as per the guidelines can be continued in the first trimester. 
However, as per a meta-analysis done by D’souza et al., this 
still remains unconfirmed.[12] As per this study, the risk of 
foetopathy if warfarin is resumed in the second trimester 
still remains around 1.4% evidenced by some studies where 
babies born had hydrocephalus or intracerebral bleed, but 
no such observation was made here. One of the patients 
was also continued on an angiotensin converting enzyme 
inhibitor, a known cause of fetal congenital anomalies, and 
the baby was born normal. This shows these drugs tend 
to exhibit more of an all or none phenomenon then cause 
anomalies in the fetuses. In a developing country like India, 
warfarin is a much more attractive option among patients on 
account of its affordability, oral intake, and inexpensive test 
for monitoring. Our observations hence show that warfarin 
can be continued as a treatment option in poor patients with 
prosthetic cardiac valves despite its slightly high risk of fetal 
anomalies and loss.
The ECHO findings of the patients are summarized as follows 
[Table 1]:
Table 1: Echocardiography findings of the patients
Patient Ejection fraction Other findings
Case I 77% Severe PAH, severe aortic valve 
gradient, good prosthetic valve function
Case II 60% Good prosthetic valve function, trivial AR
Case III 61% Good prosthetic valve function, no clot/
valve motion abnormality
Case IV 67% No prosthetic valve clot, right ventricular 
systolic dysfunction
Case V 64% Good prosthetic valve function
Case VI 60% Good prosthetic valve function, normal 
biventricular systolic function
Case VII 58% Good prosthetic valve function, normal 
biventricular systolic function
Case VIII 45% Prosthetic valve thrombosis
Discussion
The first successful human heart valve replacement was reported 
in 1960.[8] Since then, the procedure has been performed and 
has been proved to be life-saving in many individuals. With the 
increased life span of the patients receiving prosthetic valves, 
new set of unique clinical problems began to emerge, notably 
pregnancy in women of childbearing age.
In our present case series, the women were in the age group 
of 24–35 years and had no other comorbidities except 
for mechanical prosthetic cardiac valves which may have 
influenced their outcomes. Hence, there is no bias with regard 
to the events in the pregnancies of these women which were 
solely due to their condition.
None of the women in the series had a bioprosthetic heart 
valve, obviating the chance to study the effects of pregnancy on 
them. This is largely on account of their high cost precluding 
their availability in a developing country like India. There is 
also concern about the increased chances of structural valve 
deterioration with increasing age which also makes them not 
the preferred choice in young individuals. Limited studies are 
available about the outcome of pregnancies in women with 
bioprosthetic valves with mixed results.[4]
All women had rheumatic origin of their cardiac lesions 
that were mostly in the mitral valve or both mitral and 
aortic valves which is the same as for studies conducted in 
developing countries in comparison to the developed ones 
where congenital lesions are more common. This, however, 
has no effect on the anticoagulation protocols used in the 
management of these pregnancies. In a study by Sillesen et al., 
patients with corrected congenital aortic lesions tended to 
tolerate pregnancies better than others.[9] In our series, only 
one patient with a mitral valve lesion developed cardiac failure.
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As found by most studies, maternal outcome was better in 
patients on warfarin. In our series, it was found that maternal 
complications were more than the fetuses. But the two 
maternal losses took place in patients on heparin, one patient 
stopped it precoceptionally while the other took lower 
doses than prescribed. This makes warfarin a better drug of 
choice in patients with more chance of loss of follow-up or 
compliance at the risk of fetal loss.
As per D’Sousa et al.[12] and Steinberg et al.,[13] the use of 
LMWH throughout the pregnancy is associated with best 
outcome in terms of fetuses. However, only one patient in 
this series could afford the same. Also, the continuous use 
of LMWH requires the monitoring of anti-Xa heparin levels 
which may be too expensive and not readily available in all 
laboratories. Also, as these studies do not show a better 
maternal outcome with LMWH, it is not yet feasible to start 
this kind of regimen in India.
Unlike other cardiac conditions where the chances of failure 
and complications tend to be more in the second trimester, 
the two deaths occurring in the first trimester show this 
condition is high risk throughout pregnancy. Also, even 
though all patients in the series developed problems, the 
only patient among the ones with a live birth who had regular 
antenatal checkups (ANCs) in the study center from the first 
trimester had the least amount of complications. This makes 
it imperative that all patients with prosthetic heart valves 
should be managed in a tertiary care center.
Most studies included their own booked patients, but most 
patients in our study were referred either in the second or 
third trimester or when complications had set in. The one 
patient who checked in the first trimester but died due to 
valve thrombosis was found to be noncompliant. Hence, 
patients need to be referred at the earliest for treatment 
in a tertiary care center with the presence of a cardiologist 
and intensive care unit apart from specialist gynecologist 
and neonatologist.
Unlike most studies, we did not encounter any cases of fetal 
intracerebral bleed or hemorrhagic complications in any of 
the patients in our series. Earlier, it was recommended to 
go for vaginal delivery in patients with cardiac disorders 
in view of anesthetic complications.[5] But now with the 
availability of better and safer anesthetic and cardiology 
facilities, cesarean delivery in these patients has become 
a plausible alternative. As per the Van Hagen study 
on the European cardiology registry data,[14] bleeding 
complications were more in patients with cardiac valves 
particularly at the time of delivery. Hence, vaginal delivery 
should be preferred unless cesarean delivery is needed 
for obstetric indications. In our series, all mothers have 
undergone cesarean delivery for obstetric reasons and 
none of them had any such complication which indicates 
the safety of caesarean delivery in this particular group 
of patients.
The most paramount point established by our series is 
the need of strict compliance. Both patients who died 
in our series had refused to go with the medical advice 
offered. In a developing country like India with rampant 
ignorance, illiteracy, and low economic status, this can be 
a major problem. Patients are required to be counseled 
thoroughly on the need of compliance with their visits, 
treatment regimes, and doses. Most studies recommend 
an individualized regimen rather than strict adherence to 
the guidelines suggested after a discussion with the patient 
herself.[15,16,17,18] However, the factors enunciated above may 
make it particularly difficult for a protocol through patient 
discussion. Decisions may sometimes hence be needed to 
be taken empirically.
Limitations
Despite extensive searching, we were not able to find the type 
of mechanical valves used by these patients. It is assumed 
since almost all of them were on low dose of warfarin, they 
were probably using the low thrombogenic valves which are 
more prevalent now. However, as the cardiology guidelines 
do not take into account the type of valve while deciding 
on the anticoagulation drugs used and most studies too 
have not found a correlation between the type of valves and 
outcomes of these patients, we do not feel it is of significant 
consequence.
Conclusion
Maternal complications tend to be high in pregnant patients 
with prosthetic cardiac valves requiring specialized care in 
a tertiary care center with the availability of cardiology and 
specialized anesthetic services. No anticoagulation regimen 
is without any risks and it is better to give individualized 
treatment for the same with regular monitoring. The need for 
compliance cannot be overemphasized and patients should 
be counseled regarding the same.
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